The overall goal of this research is to identify efficacious strategies for treating tobacco dependence among adult smokers hospitalized with severe mental illness. Nicotine dependence is the most prevalent substance abuse disorder among psychiatric patients, a group that accounts for a staggering 44% to 46% of the US tobacco market16, 17. In terms of dollars spent, this equates to $39 billion in annual tobacco sales18. While numerous trials have established the effectiveness of smoking cessation interventions for hospitalized medical patients, little research has targeted the acute psychiatric inpatient setting19. The American Psychiatric Association's tobacco treatment guidelines identify psychiatric hospitalization as an ideal opportunity for promoting smoking cessation1. Individuals with mental illness have lower quit rates and may be less motivated and prepared to quit in the near future than the general population20-22. Thus, sufficiently intense, multi- component interventions are needed that address both the physiological and behavioral aspects of nicotine dependence and assist smokers at all stages of readiness through the quitting process23. Using a three group additive design, the proposed randomized clinical trial (N=1100) aims to evaluate tobacco cessation treatments of varying intensities initiated in the acute psychiatric inpatient setting. The proposal builds upon Dr. Prochaska's K23 mentored career development award and seeks to determine: (i) whether the initial successes seen in an academic-based psychiatric hospital can be replicated in a larger and more diverse patient population recruited from a community hospital;and (ii) if more extended and intensive clinician-delivered treatment can outperform our current best practices. The three groups are: (1) Usual Care (N=150) consisting of brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization; (2) Brief Treatment (N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization; (3) Extended Treatment (N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment. We hypothesize that the extended treatment will outperform the brief treatment, and that both treatment groups will be more effective than usual care in producing quit attempts and ultimately abstinence from cigarettes. Secondary aims will model the cost-effectiveness of the treatment conditions;examine moderators and mediators of treatment outcomes;and prospectively examine the relation between changes in smoking, mental health functioning, and use of other substances over time.

Public Health Relevance

Individuals with mental illness in the US are dying, on average, 25 years prematurely, with tobacco-related illnesses of cardiovascular and lung disease and cancer identified as chief causes24. Despite the high prevalence of smoking, low rates of quitting, and devastating health effects, clinical treatment research with smokers with mental illness remains limited. This study aims to evaluate, in a randomized controlled trial, tobacco treatments of varying intensities for smokers hospitalized on acute psychiatric inpatient units in a community hospital.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Interventions Committee for Disorders Related to Schizophrenia, Late Life, or Personality (ITSP)
Program Officer
Muehrer, Peter R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Young-Wolff, Kelly C; Karan, Lori D; Prochaska, Judith J (2015) Electronic cigarettes in jails: a panacea or public health problem? JAMA Psychiatry 72:103-4
Ramo, Danielle E; Liu, Howard; Prochaska, Judith J (2015) A mixed-methods study of young adults' receptivity to using Facebook for smoking cessation: if you build it, will they come? Am J Health Promot 29:e126-35
Ramo, Danielle E; Young-Wolff, Kelly C; Prochaska, Judith J (2015) Prevalence and correlates of electronic-cigarette use in young adults: findings from three studies over five years. Addict Behav 41:142-7
Ramo, Danielle E; Rodriguez, Theresa M S; Chavez, Kathryn et al. (2014) Facebook Recruitment of Young Adult Smokers for a Cessation Trial: Methods, Metrics, and Lessons Learned. Internet Interv 1:58-64
Mills, Edward J; Thorlund, Kristian; Eapen, Shawn et al. (2014) Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129:28-41
Prochaska, Judith J (2014) Engaging patients and clinicians in treating tobacco addiction. JAMA Intern Med 174:1299-300
Young-Wolff, Kelly C; Henriksen, Lisa; Delucchi, Kevin et al. (2014) Tobacco retailer proximity and density and nicotine dependence among smokers with serious mental illness. Am J Public Health 104:1454-63
Young-Wolff, Kelly C; Fromont, Sebastien C; Delucchi, Kevin et al. (2014) PTSD symptomatology and readiness to quit smoking among women with serious mental illness. Addict Behav 39:1231-4
Ramo, Danielle E; Delucchi, Kevin L; Liu, Howard et al. (2014) Young adults who smoke cigarettes and marijuana: analysis of thoughts and behaviors. Addict Behav 39:77-84
David, Sean P; Lancaster, Tim; Stead, Lindsay F et al. (2013) Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 6:CD003086

Showing the most recent 10 out of 23 publications